Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

Annals of Oncology

Volumn 10, Issue 6, 1999, Pages 663-669

  Giacchetti, S ^a,b   Itzhaki, M ^a   Gruia, G ^a   Adam, R ^b   Zidani, R ^a   Kunstlinger, F ^a   Brienza, S ^a   Alafaci, E ^a   Bertheault Cvitkovic, F ^a   Jasmin, C ^a   Reynes, M ^b   Bismuth, H ^b   Misset, J L ^a   Levi F ^a  

^a Service d'Oncologie Médicale   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Chronotherapy; Colorectal cancer; Liver metastases; Oxaliplatin; Surgery; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0032791959     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008347829017     Document Type: Article

References (49)

1. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993; 71: 4252-66.
2. Cady B, Stone MD. The role of surgical resection of liver metastases in colorectal carcinoma. Semin Oncol 1991; 18: 399-406.
3. Doci R, Gennari L, Bignami P et al. Morbidity and mortality after hepatic resection of metastases from colorectal cancer. J Surg 1995; 82: 377-381.
4. Gayowski TJ, Iwatsuki S, Madariaga JE et al. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-11.
5. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH. Hepatic resection for metastases from colorectal carcinoma - a survival analysis. Eur J Cancer 1995; 31A: 41-6.
6. Nordlinger B, Guiguet M, Vaillant JC et al. and Association Française de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77: 1254-62.
7. Scott S, Carty N, Anderson I, Taylor I. Liver resection for colorectal liver metastases. Eur J Surg Oncol 1995; 21: 33-5.
8. Scheithauer, Rosen H, Kornek GB et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.
9. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomised trial. J Clin Oncol 1992; 10: 904-11.
10. Köhne-Wömpner Ch, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 1992; 19: 105-25.
11. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal cancer and gastric adenocarcinoma with 5-fluorouracil and leucovorin. J Clin Oncol 1986; 4: 685-96.
12. Lokich JJ, Ahlgreen JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-atlantic oncology program study. J Clin Oncol 1989; 7: 425-32.
13. Petrelli N, Douglass H, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-26.
14. Piedbois P, Buyse M, Rustum Y et al. Modulation of fluorouracil by folinic acid in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
15. Extra JM, Espié M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
16. Pendyala L, Creaven PJ, Shah G et al. In vitro cytotoxicity studies of oxaliplatin in human tumor cell lines. Proc Am Assoc Cancer Res 1991; 32: 410 (Abstr 410).
17. Machover D, Diaz-Rubio E, De Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
18. Caussanel JP, Lévi F, Brienza S et al. Phase I trial of five-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated with constant rate. J Natl Cancer Inst 1990; 82: 1046-50.
19. Lévi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectoral cancer. A phase II study of five-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-4.
20. Becouarn Y, Ychou M, Ducreux M et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MRC) patients: Preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997; (Abstr 804).
21. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.
22. Lévi F, Zidani R, Vannetzel JM et al. chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
23. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6.
24. Brienza S, Lévi F, Valori V et al. Intensified (every two weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (LV), and oxaliplatin (L-OHP) in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 197 (Abstr 577).
25. Bertheault-Cvitkovic F, Jami A et al. Bi-weekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950-8.
26. Lévi F, Zidani R, Brienza S et al. A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and leucovorin (LV) as initial treatment of patients with colorectal cancer. Cancer 1999 (in press).
27. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1996; 7 (Suppl 5): 38 (175 P).
28. Lévi F. Chronopharmacology of anticancer agents. In Redfern PH, Lemmer B (eds): Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms, Chapt. 11: Cancer Chemotherapy. Berlin: Springer-Verlag 1997.
29. Lévi F, Soussan A, Adam R, Caussanel JP et al. A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother 1995; 5: 153.
30. Lévi F, Giacchetti S, Adam R et al. Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 1995; 31A: 1264-70.
31. Bismuth H, Adam R, Lévi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-22.
32. Wolrd Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
34. Bradpiece HA, Benjamin IS, Halevy A, Blumgart LH. Major hepatic resection for colorectal liver metastases. Br J Surg 1987; 74: 324-6.
35. Holm A, Bradley E, Aldrete JS. Hepatic resection of metastases from colorectal carcinoma morbidity, mortality, and pattern of recurrence. Ann Surg 1990; 209: 428-34.
36. Steele G, Bleday R, Mayer RJ et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal tumor study group protocol 6584. J Clin Oncol 1991; 9: 1105 12.
37. Adam R, Bismuth H, Castaing D et al. Repeat hepactectomy for colorectal liver metastases. Ann Surg 1997; 225: 51-62.
38. Fong Y, Blumgart LH, Cohen A et al. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220: 657-62.
39. Nordlinger B, Vaillant JC, Guiguet M et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. J Clin Oncol 1994; 12: 1491-6.
40. Vaillant JC, Balladur P, Nordlinger B et al. Repeat liver resection for recurrent colorectal metastases. Br J Surg 1993; 80: 340-4.
41. Adson MA. Resection of liver metastases. When is it worthwhile? World J Surg 1987; 11: 511-20.
42. Doci R, Gennari L, Bignami P et al. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis or prognostic determinants. Br J Surg 1991; 78: 797-801.
43. Earlam S, Glover C, Fordy C et al. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14: 171-5.
44. Fowler WC, Eisenberg BL, Hoffman JP. Hepatic resection follow-ing systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992; 51: 122-5.
45. Elias D, Lasser Ph, Rougier Ph et al. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumours. J Am Coll Surg 1995; 180: 213-9.
46. Meta-analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-8.
47. Lahr CJ, Soong SJ, Cloud G et al. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1983; 11: 720.
48. Rougier Ph, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82: 1397-400.
49. Stangl R, Altendorf-Hofmann A, Charnley R, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994: 343: 1405-10.